Curtis Tyree

Corporate Officer/Principal at ORGANOVO HOLDINGS, INC.

Health Technology

Profile

Dr. Curtis Tyree is a Senior VP-Strategy & Business Development at Organovo Holdings, Inc. Dr. Tyree was previously employed as a Senior Vice President-Strategic Planning by HUYA Bioscience International LLC.

Curtis Tyree active positions

Companies	Position	Start
ORGANOVO HOLDINGS, INC.	Corporate Officer/Principal	2022-02-17

All active positions of Curtis Tyree

Former positions of Curtis Tyree

Companies	Position	End
HUYA Bioscience International LLC HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA.	Corporate Officer/Principal	-

See the detail of Curtis Tyree's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Curtis Tyree's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
ORGANOVO HOLDINGS, INC.	Health Technology

Private companies	1
HUYA Bioscience International LLC HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA.	Health Technology